Researchers at MIT have developed a noninvasive, light-based blood-glucose monitoring system capable of replacing finger pricks and under the skin sensors used by patients with diabetes, reports Andrew Paul for Popular Science. The approach could “even fit on a device the size of a watch,” explains Paul. “Each measurement scan takes slightly more than 30 seconds to complete. The device also shows an accuracy comparable to two commercially available, wearable glucose monitors.”
Researchers at MIT are using AI systems to design new molecules for potential antibiotics, research that is “aimed at the growing challenge of antibiotic-resistant infections,” reports Adele Peters for Fast Company. “The number of resistant bacterial pathogens has been growing, decade upon decade,” says Prof. James Collins. “And the number of new antibiotics being developed has been dropping, decade upon decade.”
Prof. Bryan Bryson speaks with Chris Smith on The Naked Scientists podcast about his efforts to find targets for a new tuberculosis vaccine, as the current version, which is very effective in children, does not sufficiently protect adolescents and adults. “Right now, we only have one TB vaccine that's over 100 years old,” said Bryson. “And for me as an engineer, if somebody tells you there's a 100 year old technology that doesn't work the way that you want it to, you want to say, let's build a better one.”
Prof. Bryan Bryson and his colleagues have identified a series of targets for a new tuberculosis vaccine. The “researchers identified proteins expressed on the surface of cells infected with TB and used mRNA to coax uninfected human cells to produce the bacterial compounds, a key first step toward new vaccines,” writes Darren Incorvaia for Fierce Biotech.
A new study from researchers at MIT shows that lack of focus after a poor night’s sleep often corresponds with a surge of cerebrospinal fluid in the brain, which usually flows while we’re asleep. “We like to think we’re in control—that willpower, caffeine, and determination can overcome a missed night of sleep,” writes Bill Murphy Jr. for Inc. “However, this research suggests otherwise. When your brain needs to clean itself, it’s going to find a way to do it, whether you’re ready for it or not.”
Researchers at MIT examined how lack of sleep can impact a person’s attention, and “found that during these moments of brain fog, a wave of cerebrospinal fluid (CSF) is released out of the brain - a process which normally occurs whilst we are sound asleep, and helps to wash away waste products built up during the day,” reports Shaheena Uddin for The Independent.
Prof. Laura Lewis and her colleagues have discovered that momentary lapses in attention that often follow a bad night’s sleep are caused by the brain attempting to flush fluid out of its system, a process that normally occurs during sleep, reports Carissa Wong for New Scientist. “If you don’t have these waves [of fluid flowing] at night because you’re kept awake all night, then your brain starts to kind of sneak them in during the daytime, but they come with this cost of attention,” says Lewis.
Researchers at MIT have found that momentary lapses in attention, often described as zoning out, coincide with waves of fluid flowing out of the brain, reports Ian Sample for The Guardian. “The moment somebody’s attention fails is the moment this wave of fluid starts to pulse,” says Prof. Laura Lewis. “It’s not just that your neurons aren’t paying attention to the world, there’s this big change in fluid in the brain at the same time.”
Prof. Linda Griffith and her colleagues have “developed a model of the human gut to study how the organ’s microbes interact with immune cells and regulate inflammation,” reports Gemma Conroy for Nature. Griffith and her team “have also created models for endometriosis and pancreatic cancer,” writes Conroy.
In an effort to better understand how protein language models (PLMs) think and better judge their reliability, MIT researchers applied a tool called sparse autoencoders, which can be used to make large language models more interpretable. The findings “may help scientists better understand how PLMs come to certain conclusions and increase researchers’ trust in them," writes Andrea Luis for The Scientist.
Prof. Pierre Azoulay speaks with WBUR’s Martha Bebinger about a new study examining the potential impact of NIH budget cuts on the development of new medicines. Azoulay and his colleagues found that “more than half of drugs approved by the FDA since 2000 used NIH-funded research that would likely not have happened if the NIH had operated with a 40% smaller budget,” Bebinger explains.
Fierce Biotech reporter Darren Incorvaia writes that a new study by MIT researchers demonstrates how potential NIH budget cuts could endanger the development of new medications. The researchers found that if the NIH budget had been 40% smaller from 1980 to 2007, the level of NIH cuts currently being proposed, “the science underlying numerous drugs approved in the 21st century would not have been funded,” Incorvaia explains. The findings suggest that “massive cuts of the kind that are being contemplated right now could endanger the intellectual foundations of the drugs of tomorrow,” explains Professor Pierre Azoulay.
A new study co-authored by MIT researchers finds that more than half of the drugs approved by the FDA since 2000 are connected to NIH research that would be impacted by proposed 40 percent budget cuts, reports Genetic Engineering & Biotechnology News.
Using AI, researchers at MIT have developed new antibiotics for gonorrhoea and MRSA, two infections that are typically hard to treat. The team “trained the AI to help it learn how bacteria was affected by different molecular structures built of atoms in order to design new antibiotics,” writes Ruth Stainer for the Daily Mail. “[A]nything too similar to the current antibiotics available, or with the potential to be toxic to human beings, was eradicated.”
Researchers at MIT used AI to “design antibiotics that can tackle hard-to-treat infections gonorrhoea and MRSA,” reports ITV News. "Our work shows the power of AI from a drug design standpoint, and enables us to exploit much larger chemical spaces that were previously inaccessible,” says Prof. James Collins.